The Oncology Institute Net Income
| TOIIW Stock | USD 0.10 0.02 16.67% |
As of the 8th of February, Oncology Institute holds the Semi Deviation of 15.77, market risk adjusted performance of (0.45), and Coefficient Of Variation of 1037.73. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncology Institute, as well as the relationship between them. Please check The Oncology Institute semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if The Oncology Institute is priced some-what accurately, providing market reflects its current price of 0.1 per share. As The Oncology Institute appears to be a penny stock we also advise to check out its total risk alpha numbers.
Oncology Institute Total Revenue |
|
Gross Profit | Profit Margin | Revenue | Earnings Share (602.09) | Quarterly Revenue Growth 0.367 |
| Last Reported | Projected for Next Year | ||
| Net Loss | -58.2 M | -55.3 M | |
| Net Loss | -47.7 M | -45.3 M | |
| Net Loss | (0.99) | (0.94) | |
| Net Income Per E B T | 1.15 | 0.66 |
Oncology | Net Income | Build AI portfolio with Oncology Stock |
The evolution of Net Income for The Oncology Institute provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Oncology Institute compares to historical norms and industry peers.
Latest Oncology Institute's Net Income Growth Pattern
Below is the plot of the Net Income of The Oncology Institute over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in The Oncology Institute financial statement analysis. It represents the amount of money remaining after all of The Oncology Institute operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Oncology Institute's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (53.01 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Oncology Net Income Regression Statistics
| Arithmetic Mean | (14,988,261) | |
| Coefficient Of Variation | (198.67) | |
| Mean Deviation | 23,677,826 | |
| Median | 3,947,974 | |
| Standard Deviation | 29,777,345 | |
| Sample Variance | 886.7T | |
| Range | 87M | |
| R-Value | (0.77) | |
| Mean Square Error | 380.5T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (4,558,710) | |
| Total Sum of Squares | 14187T |
Oncology Net Income History
Other Fundumenentals of The Oncology Institute
Oncology Institute Net Income component correlations
Oncology Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncology Institute is extremely important. It helps to project a fair market value of Oncology Stock properly, considering its historical fundamentals such as Net Income. Since Oncology Institute's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncology Institute's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncology Institute's interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Health Care Equipment & Supplies sector? Can Oncology capture new markets? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. Valuation analysis balances hard financial data with qualitative growth assessments. While each Oncology Institute valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (602.09) | Revenue Per Share | Quarterly Revenue Growth 0.367 | Return On Assets | Return On Equity |
The Oncology Institute's market price often diverges from its book value, the accounting figure shown on Oncology's balance sheet. Smart investors calculate Oncology Institute's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Since Oncology Institute's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncology Institute 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oncology Institute's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oncology Institute.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Oncology Institute on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding The Oncology Institute or generate 0.0% return on investment in Oncology Institute over 90 days. Oncology Institute is related to or competes with Mangoceuticals Common, Synlogic, Lixte Biotechnology, Allarity Therapeutics, Entero Therapeutics, IRIDEX, and Briacell Therapeutics. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States More
Oncology Institute Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oncology Institute's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess The Oncology Institute upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 18.28 | |||
| Information Ratio | 0.0916 | |||
| Maximum Drawdown | 83.0 | |||
| Value At Risk | (26.67) | |||
| Potential Upside | 35.29 |
Oncology Institute Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncology Institute's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oncology Institute's standard deviation. In reality, there are many statistical measures that can use Oncology Institute historical prices to predict the future Oncology Institute's volatility.| Risk Adjusted Performance | 0.0872 | |||
| Jensen Alpha | 2.12 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.0945 | |||
| Treynor Ratio | (0.46) |
Oncology Institute February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0872 | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 15.27 | |||
| Semi Deviation | 15.77 | |||
| Downside Deviation | 18.28 | |||
| Coefficient Of Variation | 1037.73 | |||
| Standard Deviation | 18.85 | |||
| Variance | 355.27 | |||
| Information Ratio | 0.0916 | |||
| Jensen Alpha | 2.12 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.0945 | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 83.0 | |||
| Value At Risk | (26.67) | |||
| Potential Upside | 35.29 | |||
| Downside Variance | 334.19 | |||
| Semi Variance | 248.78 | |||
| Expected Short fall | (19.19) | |||
| Skewness | 0.1951 | |||
| Kurtosis | (0.39) |
The Oncology Institute Backtested Returns
Oncology Institute appears to be out of control, given 3 months investment horizon. The Oncology Institute maintains Sharpe Ratio (i.e., Efficiency) of 0.036, which implies the firm had a 0.036 % return per unit of risk over the last 3 months. By analyzing Oncology Institute's technical indicators, you can evaluate if the expected return of 0.67% is justified by implied risk. Please evaluate Oncology Institute's Coefficient Of Variation of 1037.73, market risk adjusted performance of (0.45), and Semi Deviation of 15.77 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Oncology Institute holds a performance score of 2. The company holds a Beta of -3.95, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncology Institute are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncology Institute is expected to outperform it. Please check Oncology Institute's sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Oncology Institute's historical price patterns will revert.
Auto-correlation | 0.30 |
Below average predictability
The Oncology Institute has below average predictability. Overlapping area represents the amount of predictability between Oncology Institute time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of The Oncology Institute price movement. The serial correlation of 0.3 indicates that nearly 30.0% of current Oncology Institute price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.3 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, The Oncology Institute reported net income of (53.01 Million). This is 115.53% lower than that of the Health Care Equipment & Supplies sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 109.28% higher than that of the company.
Oncology Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncology Institute's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncology Institute could also be used in its relative valuation, which is a method of valuing Oncology Institute by comparing valuation metrics of similar companies.Oncology Institute is currently under evaluation in net income category among its peers.
Oncology Institute Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oncology Institute from analyzing Oncology Institute's financial statements. These drivers represent accounts that assess Oncology Institute's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oncology Institute's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 645.7M | 120.1M | 150.4M | 23.2M | 26.7M | 25.3M | |
| Enterprise Value | 531.6M | 214.3M | 236.6M | 96.7M | 111.2M | 105.6M |
Oncology Fundamentals
| Return On Equity | -41.32 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.06) % | ||||
| Number Of Shares Shorted | 3.24 K | ||||
| Revenue | 393.41 M | ||||
| Gross Profit | 68.31 M | ||||
| EBITDA | (53.83 M) | ||||
| Net Income | (53.01 M) | ||||
| Cash And Equivalents | 15.17 M | ||||
| Total Debt | 123.15 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 1.76 X | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (26.54 M) | ||||
| Earnings Per Share | (602.09) X | ||||
| Number Of Employees | 825 | ||||
| Beta | 0.17 | ||||
| Total Asset | 172.72 M | ||||
| Retained Earnings | (210.81 M) | ||||
| Working Capital | 60.2 M | ||||
| Net Asset | 172.72 M |
About Oncology Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze The Oncology Institute's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncology Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of The Oncology Institute based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.